Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Large Increase in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 7,478 shares, an increase of 72.8% from the December 15th total of 4,327 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent SEC filing. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Price Performance

BRNS opened at $0.73 on Friday. Barinthus Biotherapeutics has a 12 month low of $0.64 and a 12 month high of $2.92. The business has a 50-day moving average of $0.73 and a two-hundred day moving average of $1.09. The stock has a market capitalization of $29.61 million, a price-to-earnings ratio of -0.39 and a beta of -0.66.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. Equities research analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. HC Wainwright boosted their price objective on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.